Chemotherapy of prostate cancer: Present and future

Trump, Donald L.; Lau, Yiu-Keung

doi:10.1007/s11934-003-0074-3

Cited by 12 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only this knowledge about the inefficacy of these cytoreductive regimens justifies the watch and wait strategy applied in these patients. Similarly, in many solid malignancies like prostate cancer [144][145][146], pancreatic cancer [147,148], breast cancer [149], and lung cancer [150] there is only minimal (several weeks to months), if any, impact on survival despite good clinical responses to treatment. In all these examples, it seems obvious that classical ANTI-PROLIFERATIVE therapies do not hit the cancer-initiating, and/or the cancer-perpetuating cell compartment.…”

Section: E-selectin Is Overexpressed In Breast Cancer Cells In Comparmentioning

confidence: 99%

ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology

Schmidmaier¹,

Baumann²

2008

CMC

View full text Add to dashboard Cite

Adhesion is a hallmark of haematological and solid cancer cells. All five classes of cell adhesion molecules (CAM) - integrins, cadherins, immunoglobulin-like CAMs, selectins and CD44s - are characteristically dysregulated in human cancer. Adhesion enables and promotes cancer-defining biological processes like growth, survival, migration, extravasation, homing, and metastasis. Furthermore, cell adhesion mediates drug resistance (CAM-DR) in multiple myeloma, malignant lymphoma, acute and chronic leukaemias, as well as in pancreatic cancer, neuroblastoma, small cell and non-small cell lung cancer, mesothelioma, colorectal carcinoma, and breast cancer. Cell adhesion protects from death by radiation, genotoxic chemotherapy, or targeted pathway inhibitors. Adhesion molecules are overexpressed on drug resistant cells (e.g. multiple myeloma or prostate cancer). Very recently, several cell adhesion mediated survival pathways have been elucidated, with key mediators being LFA-1, VLA-4, FAK, ILK, Src, PI3K, Akt, Ras, MEK, Erk, HMG-CoA reductase, Rho, Rho kinase, PKC, and NFkB. Because the surface and the intracellular targets are now known and because specific compounds are becoming increasingly available, first clinical trials regarding ANTI-ADHESION therapies are ongoing. However, in comparison to the comprehensive preclinical and clinical knowledge about CAMs, the number of drugs developed thusfar is quite low. ANTI-ADHESION strategies include targeting of surface antigens, inhibition of cell adhesion associated pathways, inhibition of CAM-DR, and targeted drug delivery. As ANTI-ADHESION is based on general characteristics of cancer cells independent of specific disease entities or treatment modalities, it may become a successful, low-toxic and broadly applicable concept in cancer treatment.

show abstract

Section: E-selectin Is Overexpressed In Breast Cancer Cells In Comparmentioning

confidence: 99%

ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology

Schmidmaier¹,

Baumann²

2008

CMC

View full text Add to dashboard Cite

show abstract

“…Recent investigations have followed the approach of administering calcitriol intermittently in very high doses where it still elicits its antiproliferative effects but causes only transient hypercalcemia. [51][52][53] regulates multiple genes involved in prostaglandin (PG) metabolism and signaling. 23,24 …”

Section: Clinical Trials With Calcitriolmentioning

confidence: 99%

Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer

Krishnan

Srinivas

Feldman

2009

Dermato-Endocrinology

View full text Add to dashboard Cite

“…Recent investigations have followed the approach of administering calcitriol intermittently in very high doses where it apparently can still elicit its anti-proliferative effects and cause only transient hypercalcemia. Thus far, these intermittent high doses do not appear to cause substantial toxicity [22][23][24]. Calcitriol is also being used in combination therapy with other agents that may enhance its anti-proliferative activity while reducing its hypercalcemic tendency [4].…”

Section: Clinical Trialsmentioning

confidence: 99%